Evidence map›Paper›PMID 38769201›Full record

ArticleJournal of cancer research and clinical oncology2024

Clinical significance of

Yingying Zhang, Jiangqin Han, Junpeng Li, Jinming Cao, Yeye Zhou, Shengming Deng, Bin Zhang, Yi Yang

Abstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Definitions of Incidental [Diagnostics (Basel, Switzerland) · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yingying Zhang *Department of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Jiangqin Han *Department of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Junpeng LiDepartment of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Jinming CaoDepartment of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Yeye ZhouDepartment of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Shengming DengDepartment of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Bin ZhangDepartment of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China. zbnuclmd@126.com.
Yi YangDepartment of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China. yangyi9981@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIncidental colorectal fluorodeoxyglucose (FDG) uptake, observed during positron emission tomography/computed tomography (PET/CT) scans, attracts particular attention due to its potential to represent both benign and pre-malignant/malignant lesions. Early detection and excision of these lesions are crucial for preventing cancer development and reducing mortality. This research aims to evaluate the correlation between incidental colorectal FDG uptake on PET/CT with colonoscopic and histopathological results.

methodsRetrospective analysis was performed on data from all patients who underwent PET/CT between December 2019 and December 2023 in our hospital. The study included 79 patients with incidental colonic FDG uptake who underwent endoscopy. Patient characteristics, imaging parameters, and the corresponding colonoscopy and histopathological results were studied. A comparative analysis was performed among the findings from each of these modalities. The optimal cut-off value of SUVmax for

resultsAmong the 79 patients with incidental colorectal FDG uptake, histopathology revealed malignancy in 22 (27.9%) patients and premalignant polyps in 22 (27.9%) patients. Compared to patients with benign lesions, patients with premalignant and malignant lesions were more likely to undergo a PET/CT scan for primary evaluation (p = 0.013), and more likely to have focal GIT uptake (p = 0.001) and CWT (p = 0.001). A ROC curve analysis was made and assesed a cut-off value of 7.66 SUVmax (sensitivity: 64.9% and specificity: 82.4%) to distinguish premalignant and malignant lesions from benign lesions. The AUCs of the SUVmax and the combined parameters of SUVmax and CWT were 0.758 and 0.832 respectively.

conclusionFor patients undergo PET/CT for primary evaluation, imaging features of colorectal focal FDG uptake and CWT were more closely associated with premalignant and malignant lesions. The SUVmax helps determine benign and premalignant/malignant lesions of the colorectum. Moreover, the combination of SUVmax and CWT parameters have higher accuracy in estimating premalignant and malignant lesions than SUVmax.

Indexed as

ColonoscopyFluorodeoxyglucose F18Incidental FindingsPositron Emission Tomography Computed TomographyRadiopharmaceuticalsAdultAgedAged, 80 and overClinical RelevanceColonic NeoplasmsColorectal NeoplasmsFemaleHumansMaleMiddle AgedPrecancerous ConditionsFluorodeoxyglucose F18RadiopharmaceuticalsColonoscopyColorectal cancerIncidental FDG uptakePET/CT

Identifiers

PMID38769201
PMCPMC11106158

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.